Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 1Rectal Neoplasms 1Rare Tumour 1Osteosarcoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Renal Cell Carcinoma (aRCC) 1Advanced Refractory Solid Tumors 1

Interventions

surufatinib 1irinotecan sucrosofate 1envafolimab 1anlotinib 1Vincristine 1Temozolomide 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Methotrexate 1Ifosfamide 1Etoposide 1Epirubicin 1Drug Therapy 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Osteosarcoma × envafolimab × Clear all
NCT07142863 2025-08-27

Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
23 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡